NO813492L - Medikament basert paa 2-amino-6-trifluormetoksybenzotiazol - Google Patents

Medikament basert paa 2-amino-6-trifluormetoksybenzotiazol

Info

Publication number: NO813492L
Authority: NO; Norway
Prior art keywords: amino; active substance; trifluoromethoxy; trifluorometoxybenzotiazole; benzothiazole
Prior art date: 1980-10-17

Application number

NO813492A

Other languages

English (en)

Norwegian (no)

Inventor

Jacques Mizoule

Original Assignee

Pharmindustrie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-10-17

Filing date

1981-10-16

Publication date

1982-04-19

1981-10-16 Application filed by Pharmindustrie filed Critical Pharmindustrie

1982-04-19 Publication of NO813492L publication Critical patent/NO813492L/no

Links

FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 7
230000001773 anti-convulsant effect Effects 0.000 claims description 5
239000001961 anticonvulsive agent Substances 0.000 claims description 5
230000000949 anxiolytic effect Effects 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
229960003965 antiepileptics Drugs 0.000 claims description 4
239000002249 anxiolytic agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
239000003326 hypnotic agent Substances 0.000 claims description 2
QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
239000000203 mixture Substances 0.000 description 8
206010010904 Convulsion Diseases 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
230000036461 convulsion Effects 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000008187 granular material Substances 0.000 description 6
238000000034 method Methods 0.000 description 6
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 5
241001279009 Strychnos toxifera Species 0.000 description 5
QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 5
229960005453 strychnine Drugs 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 4
239000006187 pill Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000000694 effects Effects 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229960003350 isoniazid Drugs 0.000 description 2
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
229940116357 potassium thiocyanate Drugs 0.000 description 2
239000000829 suppository Substances 0.000 description 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
241000287181 Sturnus vulgaris Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000906446 Theraps Species 0.000 description 1
YGCODSQDUUUKIV-UHFFFAOYSA-N Zoxazolamine Chemical compound ClC1=CC=C2OC(N)=NC2=C1 YGCODSQDUUUKIV-UHFFFAOYSA-N 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000003371 gabaergic effect Effects 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000155 melt Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000002547 new drug Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000723 toxicological property Toxicity 0.000 description 1
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
229960000604 valproic acid Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229950006967 zoxazolamine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicinal Preparation (AREA)

NO813492A 1980-10-17 1981-10-16 Medikament basert paa 2-amino-6-trifluormetoksybenzotiazol NO813492L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR8022218A FR2492258A1 (fr)	1980-10-17	1980-10-17	Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole

Publications (1)

Publication Number	Publication Date
NO813492L true NO813492L (no)	1982-04-19

Family

ID=9247013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO813492A NO813492L (no)	1980-10-17	1981-10-16	Medikament basert paa 2-amino-6-trifluormetoksybenzotiazol

Country Status (16)

Country	Link
US (1)	US4370338A (de)
EP (1)	EP0050551B1 (de)
JP (1)	JPS5795910A (de)
AR (1)	AR227069A1 (de)
AU (1)	AU545437B2 (de)
CA (1)	CA1166159A (de)
DE (1)	DE3163230D1 (de)
DK (1)	DK444281A (de)
FR (1)	FR2492258A1 (de)
GR (1)	GR75804B (de)
HU (1)	HU184893B (de)
IL (1)	IL63880A0 (de)
MA (1)	MA19364A1 (de)
NO (1)	NO813492L (de)
PT (1)	PT73828B (de)
ZA (1)	ZA817187B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826860A (en) *	1987-03-16	1989-05-02	Warner-Lambert Company	Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
FR2619713B1 (fr) *	1987-08-25	1990-08-31	Rhone Poulenc Sante	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
FR2619712B1 (fr) *	1987-08-25	1990-08-31	Rhone Poulenc Sante	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie
FR2640624B1 (fr) *	1988-12-15	1994-08-12	Rhone Poulenc Sante	Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
US5236940A (en) *	1988-12-15	1993-08-17	Rhone-Poulenc Sante	Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
FR2640622B1 (fr) *	1988-12-15	1991-03-22	Rhone Poulenc Sante	Derives de l'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
ES2043070T3 (es) *	1988-12-15	1993-12-16	Rhone Poulenc Sante	Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
FR2640623B1 (fr) *	1988-12-15	1991-03-22	Rhone Poulenc Sante	Derives de la benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2649705B2 (fr) *	1989-07-13	1994-09-23	Rhone Poulenc Sante	Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
FR2649701B2 (fr) *	1988-12-15	1991-11-22	Rhone Poulenc Sante	Derives d'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2649703B1 (fr) *	1989-07-13	1991-11-22	Rhone Poulenc Sante	Derives d'imino-2 polyfluoroalcoxy-6 benzothiazole, leurs procedes de preparation et les medicaments les contenant
ES2052954T3 (es) *	1988-12-15	1994-07-16	Rhone Poulenc Sante	Derivados de imino-2-polifluoroalcoxi-6-benzotiazol, sus procedimientos de preparacion y los medicamentos que les contienen.
US5260297A (en) *	1989-07-13	1993-11-09	Rhone Poulenc Rorer, S.A.	2-imino-3-alkylbenzothiazoline derivatives bearing a heterocyclic substituent on the alkyl group, their preparation and medicinal products containing them.
FR2649702B1 (fr) *	1989-07-13	1991-11-22	Rhone Poulenc Sante	Derives d'alkylimino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
ES2062445T3 (es) *	1989-07-13	1994-12-16	Rhone Poulenc Sante	Derivados de imino-2 heterociclilalquil-3 benzotiazolina, su preparacion y los medicamentos que les contienen.
FR2649704B1 (fr) *	1989-07-13	1991-11-22	Rhone Poulenc Sante	Derives d'imino-2 ethyl-3 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2661910B1 (fr) *	1990-05-11	1992-08-21	Rhone Poulenc Sante	Derives d'imino-2 heterocyclylalkyl-3 benzothiazoline, leur preparation et les medicaments les contenant.
FR2662160B1 (fr) *	1990-05-18	1992-07-24	Rhone Poulenc Sante	Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
FR2663030A1 (fr) *	1990-06-05	1991-12-13	Rhone Poulenc Sante	Derives selenies de benzothiazoline leur preparation et les medicaments les contenant.
FR2662694A1 (fr) *	1990-06-05	1991-12-06	Rhone Poulenc Sante	Derives du benzoselenazole, leur preparation et les medicaments les contenant.
FR2662695A1 (fr) *	1990-06-05	1991-12-06	Rhone Poulenc Sante	Amino-2 polyfluoroalcoxy-6 benzoselenazoles, leur preparation et les medicaments les contenant.
FR2663029B1 (fr) *	1990-06-07	1992-07-31	Rhone Poulenc Sante	Derives de benzothiazole, leur preparation et les medicaments les contenant.
FR2688138B1 (fr) *	1992-03-06	1995-05-05	Rhone Poulenc Rorer Sa	Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
FR2699077B1 (fr) *	1992-12-16	1995-01-13	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700117B1 (fr) *	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2700116B1 (fr) *	1993-01-07	1995-02-03	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants comme radioprotecteurs.
FR2702148B1 (fr) *	1993-03-05	1995-04-07	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2726271B1 (fr) *	1994-10-26	1996-12-06	Rhone Poulenc Rorer Sa	Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole
FR2786101B1 (fr)	1998-11-24	2002-07-05	Aventis Laboratoire	Utilisation de la nicergoline dans le traitement de la spasticite
FR2787028B1 (fr)	1998-12-15	2002-10-18	Aventis Pharma Sa	Utilisation du riluzole dans le traitement des traumatismes acoustiques
EP1142584A4 (de) *	1999-01-12	2003-04-16	Takeda Chemical Industries Ltd	Zusammensetzungen zur behandlung häufigen harnlassens sowie harninkontinenz
AP2001002359A0 (en)	2000-11-30	2001-12-31	Pfizer Prod Inc	Combination of gaba agonists and aldose reductase inhibitors.
KR20030059290A (ko) *	2000-11-30	2003-07-07	화이자 프로덕츠 인코포레이티드	Ｇａｂａ 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물
EP2316468A1 (de)	2002-02-22	2011-05-04	Shire LLC	Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
CA2525366A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
PT1691811E (pt)	2003-12-11	2014-10-30	Sunovion Pharmaceuticals Inc	Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
BRPI0507190A (pt) *	2004-01-29	2007-06-26	Pfizer Prod Inc	combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
ES2819303T3 (es) *	2005-04-05	2021-04-15	Univ Yale	Agentes moduladores del glutamato en el tratamiento de trastornos mentales
EP1924326B1 (de)	2005-08-25	2016-10-12	Steven Michael Weiss	Reduzierung von myokard-schaden und inzidenz von arrhythmien durch verlust, verringerung oder unterbrechung des koronaren blutflusses
EP2258357A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275096A3 (de)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (de)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
CA2643199A1 (en) *	2006-03-08	2007-09-13	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (de)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenese mittels angiotensin-modulation
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
US20100009983A1 (en) *	2006-05-09	2010-01-14	Braincells, Inc.	5 ht receptor mediated neurogenesis
WO2008030651A1 (en) *	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (de) *	2006-09-19	2009-06-10	Braincells, Inc.	Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20080108827A1 (en) *	2006-10-25	2008-05-08	Padi Pratap R	Process for preparing riluzole
DK2083811T3 (en)	2006-11-22	2017-01-30	Clinical Res Ass Llc	PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
US20090167322A1 (en) *	2007-12-28	2009-07-02	Erik Edmund Magnuson	Systems and method for classifying a substance
WO2009121759A2 (en) *	2008-04-03	2009-10-08	F. Hoffmann-La Roche Ag	Use of pegylated igf-i variants for the treatment of neuromuscular disorders
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP2284161A1 (de)	2009-07-21	2011-02-16	Edmond Pharma S.R.L.	Verfahren zur Herstellung von Riluzol
CA2967659A1 (en) *	2014-11-21	2016-05-26	Biohaven Pharmaceutical Holding Company Ltd.	Sublingual administration of riluzole
RS59490B1 (sr) *	2014-11-21	2019-12-31	Biohaven Therapeutics Ltd	Sublingvalna formulacija riluzola
CN108283000B (zh)	2015-09-23	2021-04-13	凯瑞康宁生物工程（武汉）有限公司	γ-羟基丁酸的前药及其组合物和用途
TWI788307B (zh)	2016-10-31	2023-01-01	美商艾歐凡斯生物治療公司	用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
ES3055314T3 (en)	2017-01-06	2026-02-11	Iovance Biotherapeutics Inc	Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
KR102510784B1 (ko) *	2017-03-30	2023-03-15	엑스더블유파마 리미티드	이환형 헤테로아릴 유도체 및 이의 제조 및 용도
CN114042070A (zh)	2018-09-30	2022-02-15	凯瑞康宁生物工程（武汉）有限公司	作为神经元组胺受体-3拮抗剂的化合物及其用途
WO2021127461A1 (en)	2019-12-20	2021-06-24	Xw Laboratories Limited	Methods of synthesizing 4-valyloxybutyric acid
KR102982616B1 (ko)	2020-06-18	2026-06-26	엑스더블유파마 리미티드	수용성 원료의약품의 약학적 과립화제
AU2021292406B2 (en)	2020-06-18	2024-03-14	XWPharma Ltd.	Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en)	2020-07-24	2022-01-27	XWPharma Ltd.	Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en)	2020-10-05	2024-09-26	XWPharma Ltd.	Modified release compositions of a gamma-hydroxybutyric acid derivative
DK4308086T3 (da)	2021-03-19	2025-11-17	Xwpharma Ltd	Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3879531A (en) *	1972-07-17	1975-04-22	Uniroyal Inc	2-aminothiazoles compositions and methods for using them as psychotherapeutic agents
US3876653A (en) *	1973-03-26	1975-04-08	Kyowa Hakko Kogyo Kk	Benzothiazole derivatives

1980
- 1980-10-17 FR FR8022218A patent/FR2492258A1/fr active Granted
1981
- 1981-09-18 IL IL63880A patent/IL63880A0/xx not_active IP Right Cessation
- 1981-10-01 GR GR66186A patent/GR75804B/el unknown
- 1981-10-05 US US06/308,695 patent/US4370338A/en not_active Expired - Lifetime
- 1981-10-07 DK DK444281A patent/DK444281A/da not_active Application Discontinuation
- 1981-10-09 EP EP81401564A patent/EP0050551B1/de not_active Expired
- 1981-10-09 DE DE8181401564T patent/DE3163230D1/de not_active Expired
- 1981-10-15 PT PT73828A patent/PT73828B/pt unknown
- 1981-10-15 CA CA000387977A patent/CA1166159A/fr not_active Expired
- 1981-10-16 MA MA19508A patent/MA19364A1/fr unknown
- 1981-10-16 NO NO813492A patent/NO813492L/no unknown
- 1981-10-16 JP JP56165586A patent/JPS5795910A/ja active Granted
- 1981-10-16 HU HU812994A patent/HU184893B/hu not_active IP Right Cessation
- 1981-10-16 AU AU76545/81A patent/AU545437B2/en not_active Ceased
- 1981-10-16 ZA ZA817187A patent/ZA817187B/xx unknown
- 1981-10-19 AR AR287142A patent/AR227069A1/es active

Also Published As

Publication number	Publication date
GR75804B (de)	1984-08-02
US4370338A (en)	1983-01-25
EP0050551A1 (de)	1982-04-28
FR2492258A1 (fr)	1982-04-23
HU184893B (en)	1984-10-29
EP0050551B1 (de)	1984-04-18
ZA817187B (en)	1982-09-29
DE3163230D1 (en)	1984-05-24
JPH0148884B2 (de)	1989-10-20
PT73828A (fr)	1981-11-01
MA19364A1 (fr)	1982-07-01
FR2492258B1 (de)	1982-11-26
CA1166159A (fr)	1984-04-24
AU7654581A (en)	1982-04-22
PT73828B (fr)	1983-01-17
AR227069A1 (es)	1982-09-15
IL63880A0 (en)	1981-12-31
DK444281A (da)	1982-04-18
AU545437B2 (en)	1985-07-11
JPS5795910A (en)	1982-06-15

Publication	Publication Date	Title
US4370338A (en)	1983-01-25	Medicament based on 2-amino-6-trifluoromethoxy-benzothiazole
US4455298A (en)	1984-06-19	Pharmaceutical preparations with gastro-protective action
CZ295495A3 (en)	1996-02-14	Pharmaceutical preparation and process for preparing thereof
US4226861A (en)	1980-10-07	N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides
MXPA01011071A (es)	2002-07-22	Composicion farmaceutica en forma unitaria que contiene acido acetilsalicilico e hidrogenosulfato de clopidogrel.
SK281193B6 (sk)	2001-01-18	Tableta so zlepšenou biodostupnosťou účinnej látky, kyseliny klodrónovej, spôsob jej výroby a použitie mikrokryštalickej celulózy
JPS63130569A (ja)	1988-06-02	カルボン酸アミド含有薬剤
KR100310041B1 (ko)	2002-04-24	틸리딘이수소오르토포스페이트,그제조방법및이를함유한의약제제
IE891908L (en)	1989-12-28	Novel esters
US3923994A (en)	1975-12-02	Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity
BE882315A (fr)	1980-09-19	Composes de 6-aryl pyrimidine, leur preparation et leur utilisation
JPS6222785A (ja)	1987-01-30	新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
CN100422133C (zh)	2008-10-01	2-（α-羟基戊基）苯甲酸盐及其制法和用途
EP0123520B1 (de)	1988-08-17	Verfahren zur Herstellung von abgesetzten, basischen Piroxicam-Salzen auf einem pharmazeutisch annehmbaren Träger
US2931814A (en)	1960-04-05	4-alkylpyrazoles
US2926170A (en)	1960-02-23	Certain 1-acyl-3-undecyl pyrazoles
RU2090555C1 (ru)	1997-09-20	Производные мочевины, способ получения производных мочевины, фармацевтическая композиция, обладающая ингибирующей активностью в отношении coa : холестерин-ацилтрансферазы (асат)
RU2008015C1 (ru)	1994-02-28	Способ получения витаминного средства "витапектин"
US4001424A (en)	1977-01-04	1-Oxo-1H-naphtho [2,1-b] pyran derivatives for treating depression
GB2154233A (en)	1985-09-04	Aluminium salts of arylalkanoic acids and pharmaceutical compositions containing them
JP3090211B2 (ja)	2000-09-18	第４級ｎ−ベンジル−ｎ−｛２−〔２−（（１ｓ，５ｓ）−６，６−ジメチルビシクロ〔３．１．１〕−ヘプト−２−イル）エトキシ〕エチル｝モルホリニウム塩を含有する胃保護作用を有する製薬学的調剤およびその製造法
US3787440A (en)	1974-01-22	3-sulfamyl-4-chlorobenzoic acid derivatives
US3639597A (en)	1972-02-01	Pharmaceutical compositions containing cholanic acid conjugates
RU2118529C1 (ru)	1998-09-10	Ветеринарный препарат "трикаптол" для лечения гастроэнтеритов молодняка сельскохозяйственных животных
IL51472A (en)	1980-06-30	Pharmaceutical compositions comprising the salicylamide ester of aspirin and process for the preparation of this compound